{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+B&page=5",
    "query": {
      "intervention": "Placebo Comparator B",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 2823,
    "total_pages": 283,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+B&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator+B&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T21:35:58.561Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04167345",
      "title": "Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "VX-814",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 48,
      "start_date": "2020-01-13",
      "completion_date": "2020-11-14",
      "has_results": true,
      "last_update_posted_date": "2022-02-02",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Denver, Colorado + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04167345"
    },
    {
      "nct_id": "NCT02471144",
      "title": "Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Severe Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "Experimental : Secukinumab low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: Secukinumab high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Comparator: Secukinumab Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Comparator: Etanercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 162,
      "start_date": "2015-09-29",
      "completion_date": "2023-03-30",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02471144"
    },
    {
      "nct_id": "NCT01076764",
      "title": "Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Otamixaban",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Otamixaban)",
          "type": "DRUG"
        },
        {
          "name": "UFH",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for UFH)",
          "type": "DRUG"
        },
        {
          "name": "Eptifibatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Eptifibatide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13220,
      "start_date": "2010-04",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2016-05-04",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 107,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01076764"
    },
    {
      "nct_id": "NCT02346747",
      "title": "A Trial of Vigil for Participants With Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Vigil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 92,
      "start_date": "2015-02",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Irvine, California • San Francisco, California + 22 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02346747"
    },
    {
      "nct_id": "NCT03175367",
      "title": "Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evinacumab",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Background Lipid Modifying Therapy (LMT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 272,
      "start_date": "2017-11-10",
      "completion_date": "2020-12-14",
      "has_results": true,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03175367"
    },
    {
      "nct_id": "NCT01463098",
      "title": "A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "E2006 1.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 5.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 10.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 25.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 50.0 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 100 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Zolpidem 10 mg",
          "type": "DRUG"
        },
        {
          "name": "E2006 Matched Placebo or Zolpidem Matched Placebo",
          "type": "DRUG"
        },
        {
          "name": "E2006 Matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 122,
      "start_date": "2011-10-05",
      "completion_date": "2012-08-11",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 2,
      "location_summary": "New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01463098"
    },
    {
      "nct_id": "NCT00611806",
      "title": "Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Folic Acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "B12",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "68 Years",
        "sex": "ALL",
        "summary": "18 Years to 68 Years"
      },
      "enrollment_count": 140,
      "start_date": "2007-12",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-08-19",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Grand Rapids, Michigan • Rochester, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611806"
    },
    {
      "nct_id": "NCT04684914",
      "title": "HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B, Chronic"
      ],
      "interventions": [
        {
          "name": "HepTcell",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Altimmune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 87,
      "start_date": "2020-12-26",
      "completion_date": "2024-04-17",
      "has_results": true,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 5,
      "location_summary": "Garden Grove, California • Redwood City, California • San Jose, California + 2 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684914"
    },
    {
      "nct_id": "NCT01352793",
      "title": "A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis, Meningococcal"
      ],
      "interventions": [
        {
          "name": "rLP2086 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 5715,
      "start_date": "2012-11",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-03-11",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 39,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01352793"
    },
    {
      "nct_id": "NCT07076121",
      "title": "A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Navlimetostat",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 470,
      "start_date": "2025-10-23",
      "completion_date": "2029-05-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-11-18T21:35:58.561Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07076121"
    }
  ]
}